TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$86.3 Million

Terns Pharmaceuticals, Inc.

Follow-on Offering

Bookrunner, December 2022

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. (“Terns”) is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH). Tern’s programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with large unmet needs.